Aura Biosciences (AURA) to Release Quarterly Earnings on Monday

Aura Biosciences (NASDAQ:AURA) is projected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $6.55 on Friday. The business’s fifty day moving average price is $5.69 and its two-hundred day moving average price is $5.86. The stock has a market cap of $415.93 million, a PE ratio of -3.38 and a beta of 0.45. Aura Biosciences has a one year low of $4.34 and a one year high of $7.73.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on AURA. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 29th. Evercore started coverage on Aura Biosciences in a report on Tuesday, November 25th. They set an “outperform” rating on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aura Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 15,890 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $5.05, for a total value of $80,244.50. Following the completion of the sale, the chief technology officer directly owned 181,397 shares in the company, valued at $916,054.85. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Amy Elazzouzi sold 8,549 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total value of $43,257.94. Following the completion of the transaction, the senior vice president directly owned 75,532 shares in the company, valued at $382,191.92. The trade was a 10.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,076 shares of company stock worth $618,783 in the last three months. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Several large investors have recently bought and sold shares of AURA. Tower Research Capital LLC TRC lifted its holdings in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after acquiring an additional 2,104 shares during the period. Water Island Capital LLC bought a new position in shares of Aura Biosciences in the third quarter valued at approximately $64,000. Invesco Ltd. bought a new position in shares of Aura Biosciences in the second quarter valued at about $76,000. BNP Paribas Financial Markets lifted its position in shares of Aura Biosciences by 286.6% during the second quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company’s stock worth $85,000 after purchasing an additional 10,007 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in Aura Biosciences during the 2nd quarter worth $102,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.